U.S. Markets closed
  • S&P 500

    -31.16 (-0.72%)
  • Dow 30

    -171.69 (-0.50%)
  • Nasdaq

    -164.43 (-1.25%)
  • Russell 2000

    -33.22 (-1.64%)
  • Crude Oil

    -0.52 (-0.59%)
  • Gold

    +1.30 (+0.07%)
  • Silver

    +0.00 (+0.02%)

    +0.0010 (+0.1018%)
  • 10-Yr Bond

    +0.0690 (+2.44%)
  • Vix

    +0.21 (+1.07%)

    -0.0044 (-0.3639%)

    +0.8500 (+0.6333%)

    -508.96 (-2.13%)
  • CMC Crypto 200

    -15.58 (-2.72%)
  • FTSE 100

    -20.31 (-0.27%)
  • Nikkei 225

    +353.86 (+1.23%)

Black Bird Biotech Announces Second Successful MiteXstream Honey Bee Test Results: Not Toxic to Honey Bees When Ingested

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

FLOWER MOUND, TX / ACCESSWIRE / June 7, 2022 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer of plant-based MiteXstreamTM biopesticide, today announced that, in additional independent lab testing, MiteXstreamTM was proven to be "NOT TOXIC" to honey bees when they ingest the biopesticide. The Honey Bee Report on Oral Toxicity can be found here.

The company had previously announced that MiteXstreamTM tested as "NOT TOXIC" to honey bees when contacted topically (report can be found here).

"MiteXstreamTM is now lab proven to be completely non-toxic to bees. This, coupled with its high efficacy and cost-effectiveness, will provide us leverage as we seek to expand sales channels," said Fabian Deneault, BBBT's President. "These results demonstrate the game-changing capabilities that MiteXstreamTM brings to the many facets of the agricultural industry."

Performing Lab:

STILLMEADOW, Inc., Sugar Land, Texas.

Study Director:

Cole Younger, PhD., Entomologist, STILLMEADOW, Inc.

The Study:

MiteXstream: Honey bee, Apis mellifera, Acute Oral Toxicity Limit Test.

The Conclusion:

With a mortality of 0% after 48 hours, MiteXstream was non-toxic when ingested by honey bees.

According to Fortune Business Insights™, the Biopesticides Market is forecast to be worth $10.63 Billion for 2027, with a CAGR at 13.1%, which growth will be boosted by rising research activities to develop new microbial products.

A USDA report stated, "As the world's most important group of pollinators, bees are a crucial part of agricultural production and natural ecosystem function."

Black Bird Biotech is proud to offer the MiteXstreamTM product that is both an effective means of controlling pests, including spider mites, molds and other harmful agricultural issues while testing as not-toxic to honey bees.

MiteXstreamTM is currently available at MiteXstream.com and in the MiteXstream Amazon® Store.

For news and updates, shareholders, prospective investors and prospective business partners are encouraged to follow @BBBT_Corporate on Twitter and @BlackBirdBiotech on Instagram. Also visit BBBT's corporate website, BlackBirdBiotech.com, for additional information about the company.

Black Bird Biotech, Inc., Tuesday, June 7, 2022, Press release picture
Black Bird Biotech, Inc., Tuesday, June 7, 2022, Press release picture

About BBBT

Black Bird Biotech is positioned to exploit market segments with powerful, re-imagined biotech products. Its EPA-registered biopesticide, MiteXstreamTM, eradicates mites and similar pests, including spider mites (a lethal pest in cannabis, grapes, hops, coffee, strawberries and many other agricultural crops), and eliminates molds and mildews. MiteXstreamTM is a pesticide, but it is not a poison - it's a pesticide re-imagined. The MiteXstreamTM Edge: use through the day of harvest without concern for residual "pesticide" violations, including as it pertains to state cannabis testing. MiteXstreamTM is the foundational element of the company that carries vast potential worldwide as a highly effective, safe and extremely cost-effective replacement for many traditional "poisonous" pesticides.

Forward Looking Statements:

This current press release contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, any products sold or cash flow from operations.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with distribution and difficulties associated with obtaining financing on acceptable terms. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Eric Newlan
Vice President

SOURCE: Black Bird Biotech, Inc.

View source version on accesswire.com: